君實生物(01877.HK)擬成立合資從事小分子抗腫瘤藥物研發和商業化
格隆匯 8 月 20日丨君實生物(01877.HK)宣佈,於2020年8月19日,公司與南京英派藥業就成立合資公司訂立合資協議。合資公司將主要從事小分子抗腫瘤藥物研發和商業化。於其成立後,合資公司將分別由公司及南京英派藥業擁有50%及50%的權益。
合資公司的中文名稱擬為英實君派藥業有限公司,須經市場監督管理局批准,註冊資本不超過人民幣2億元。合資公司將主要從事小分子抗腫瘤藥物研發和商業化(主要通過外包合同研究、生產或銷售組織)。合資公司的業務範圍將包括:醫學研究和試驗發展(人體幹細胞、基因診斷與治療技術除外);醫用新材料、醫療器械、生物技術產品、新藥的研發及銷售;生物技術開發與轉讓、生物分析與化學合成技術研發及技術服務;儀器設備、試劑(不含危險品)批發、技術進出口;貨物進出口。
作為合資公司的股東,南京英派藥業已開發出已顯示安全性的新型PARP抑制劑,而公司會就臨牀開發及商業化對合資公司作出注資。公司認為,成立合資公司可創造協同效應,且公司可透過訂立合資協議自IMP4297項目獲得長期利益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.